Literature DB >> 26257405

The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer.

A Scharl1, T Kühn2, T Papathemelis1, A Salterberg3.   

Abstract

The probability of healing breast cancer has been greatly improved in recent decades through the introduction and optimisation of multi-modal therapies and interdisciplinary treatments. Today, in addition to surgery or radiation, most patients receive a systemic treatment. To prevent excessive treatment, patients whose prognosis is so good that certain adjuvant therapies can be foregone or reduced must be identified. A lack of compliance with therapy, especially in the endocrine therapies stretching over years, is a further problem. As only treatments that are also carried out can improve chances of survival, efforts to improve compliance must be intensified. Studies show that lifestyle changes influence the efficiency of medication on the one hand, and on the other hand can also by themselves achieve a relevant improvement of the prognosis. Therefore, it is time not only to treat the tumour, but to also focus on the patient as a whole in therapeutic interventions.

Entities:  

Keywords:  breast cancer; compliance; excessive treatment; lifestyle changes; over-diagnosis

Year:  2015        PMID: 26257405      PMCID: PMC4520989          DOI: 10.1055/s-0035-1546270

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  35 in total

1.  Are Physicians Choosing Wisely When Imaging for Distant Metastases in Women With Operable Breast Cancer?

Authors:  Demetrios Simos; Brian Hutton; Mark Clemons
Journal:  J Oncol Pract       Date:  2014-11-12       Impact factor: 3.840

2.  Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

Authors:  Ian H Kunkler; Linda J Williams; Wilma J L Jack; David A Cameron; J Michael Dixon
Journal:  Lancet Oncol       Date:  2015-01-28       Impact factor: 41.316

3.  An individual person data meta-analysis of preoperative magnetic resonance imaging and breast cancer recurrence.

Authors:  Nehmat Houssami; Robin Turner; Petra Macaskill; Lindsay W Turnbull; David R McCready; Todd M Tuttle; Neha Vapiwala; Lawrence J Solin
Journal:  J Clin Oncol       Date:  2014-01-06       Impact factor: 44.544

4.  Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy.

Authors:  Melissa Pilewskie; Alice Ho; Emily Orell; Michelle Stempel; Yu Chen; Anne Eaton; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2013-12-11       Impact factor: 5.344

5.  Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis.

Authors:  P Hadji; V Ziller; J Kyvernitakis; M Bauer; G Haas; N Schmidt; K Kostev
Journal:  Breast Cancer Res Treat       Date:  2013-01-20       Impact factor: 4.872

6.  Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread.

Authors:  Bernd Gerber; Eva Seitz; Heiner Müller; Annette Krause; Toralf Reimer; Günther Kundt; Klaus Friese
Journal:  Breast Cancer Res Treat       Date:  2003-11       Impact factor: 4.872

7.  Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Authors:  Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

Review 8.  Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Authors:  C Correa; P McGale; C Taylor; Y Wang; M Clarke; C Davies; R Peto; N Bijker; L Solin; S Darby
Journal:  J Natl Cancer Inst Monogr       Date:  2010

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

10.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

View more
  4 in total

1.  Supporting breast cancer decisions using formalized guidelines and experts decision patterns: initial prototype and evaluation.

Authors:  Dennis Andrzejewski; Rüdiger Breitschwerdt; Michael Fellmann; Eberhard Beck
Journal:  Health Inf Sci Syst       Date:  2017-10-30

Review 2.  Significance of Ovarian Function Suppression in Endocrine Therapy for Breast Cancer in Pre-Menopausal Women.

Authors:  A Scharl; A Salterberg
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-05       Impact factor: 2.915

3.  Cannabinoid Combination Induces Cytoplasmic Vacuolation in MCF-7 Breast Cancer Cells.

Authors:  Recardia Schoeman; Natasha Beukes; Carminita Frost
Journal:  Molecules       Date:  2020-10-14       Impact factor: 4.411

4.  Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.

Authors:  Michael G Schrauder; Lisa Brunel-Geuder; Lothar Häberle; Marius Wunderle; Juliane Hoyer; Roland Csorba; André Reis; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Michael P Lux
Journal:  Eur J Med Res       Date:  2019-09-14       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.